• to lessen the risk of significant cardiovascular (heart and blood vessel) problems in Grown ups with type two diabetes and heart problemsThis led Novo Nordisk to carry out even further investigate into bigger dosages of semaglutide specifically for weight management.By 2022 the popularity of Novo's Wegovy and copyright for weight loss was so gr